Immune-related adverse events with immune checkpoint blockade: A comprehensive review

European Journal of Cancer

Volumn 54, Issue , 2016, Pages 139-148

  Michot, J M ^a,b   Bigenwald, C ^a   Champiat, S ^a   Collins, M ^b,c   Carbonnel, F ^b,c   Postel Vinay, S ^a   Berdelou, A ^a   Varga, A ^a   Bahleda, R ^a   Hollebecque, A ^a   Massard, C ^a   Fuerea, A ^a   Ribrag, V ^a   Gazzah, A ^a   Armand, J P ^a   Amellal, N ^a   Angevin, E ^a   Noel, N ^b,c,d,e   Boutros, C ^a,b   Mateus, C ^a,b   Robert, C ^a,b   Soria, J C ^a   Marabelle, A ^a   Lambotte, O ^b,c,d,e   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^e INSERM   (France)

Author keywords

Anti PD 1 antibody; Cytotoxic T lymphocyte associated antigen 4; Immune checkpoint blockade; Immune related adverse events; Tumour neoantigen

Indexed keywords

BIOLOGICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNE CHECKPOINT BLOCKER; IMMUNOMODULATING AGENT; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; STEROID; UNCLASSIFIED DRUG; ABATACEPT; ANTIBODY; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN;

BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; DRUG EFFICACY; DRUG EXPOSURE; EYE TOXICITY; GASTROINTESTINAL DISEASE; HUMAN; HYPOPHYSITIS; IMMUNE RELATED ADVERSE EVENT; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; LIVER TOXICITY; LUNG TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; ONCOLOGIST; PANCREAS DISEASE; POLYARTHRITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; TARGET CELL; THYROID DISEASE; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES; RISK FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ABATACEPT; ANIMALS; ANTIBODIES; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84953309212     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.11.016     Document Type: Review

References (79)

1. I. Mellman, G. Coukos, and G. Dranoff Cancer immunotherapy comes of age Nature 480 2011 480 489 10.1038/nature10673
2. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723 10.1056/NEJMoa1003466
3. C. Robert, G.V. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, and et al. Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 2015 320 330 10.1056/NEJMoa1412082
4. C. Robert, J. Schachter, G.V. Long, A. Arance, J.J. Grob, L. Mortier, and et al. Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 2015 10.1056/NEJMoa1503093
5. C. Devaud, L.B. John, J.A. Westwood, P.K. Darcy, and M.H. Kershaw Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy Oncoimmunology 2 2013 e25961 10.4161/onci.25961
6. H.S. Kuehn, W. Ouyang, B. Lo, E.K. Deenick, J.E. Niemela, D.T. Avery, and et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4 Science 345 2014 1623 1627 10.1126/science.1255904
7. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis. J Clin Oncol n.d.
8. H. Ueda, J.M.M. Howson, L. Esposito, J. Heward, H. Snook, G. Chamberlain, and et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease Nature 423 2003 506 511 10.1038/nature01621
9. L. Prokunina, C. Castillejo-López, F. Oberg, I. Gunnarsson, L. Berg, V. Magnusson, and et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans Nat Genet 32 2002 666 669 10.1038/ng1020
10. T.W. Chen, A.R. Razak, P.L. Bedard, L.L. Siu, and A.R. Hansen A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors† Ann Oncol Off J Eur Soc Med Oncol ESMO 26 2015 1824 1829 10.1093/annonc/mdv182
11. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454 10.1056/NEJMoa1200690
12. G.Y. Ku, J. Yuan, D.B. Page, S.E.A. Schroeder, K.S. Panageas, R.D. Carvajal, and et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival Cancer 116 2010 1767 1775 10.1002/cncr.24951
13. T.F. Gajewski, J. Louahed, and V.G. Brichard Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy Cancer J Sudbury Mass 16 2010 399 403 10.1097/PPO.0b013e3181eacbd8
14. E. Cha, M. Klinger, Y. Hou, C. Cummings, A. Ribas, M. Faham, and et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients Sci Transl Med 6 2014 238ra70 10.1126/scitranslmed.3008211
15. A. Snyder, V. Makarov, T. Merghoub, J. Yuan, J.M. Zaretsky, A. Desrichard, and et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma N Engl J Med 371 2014 2189 2199 10.1056/NEJMoa1406498
16. M. Vétizou, J.M. Pitt, R. Daillère, P. Lepage, N. Waldschmitt, C. Flament, and et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota Science 2015 10.1126/science.aad1329
17. J.R. Brahmer, S.S. Tykodi, L.Q.M. Chow, W.-J. Hwu, S.L. Topalian, P. Hwu, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465 10.1056/NEJMoa1200694
18. J.S. Weber, R. Dummer, V. de Pril, C. Lebbé, F.S. Hodi MDX010-20 Investigators Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma Cancer 119 2013 1675 1682 10.1002/cncr.27969
19. S.L. Topalian, M. Sznol, D.F. McDermott, H.M. Kluger, R.D. Carvajal, W.H. Sharfman, and et al. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab J Clin Oncol 32 2014 1020 1030 10.1200/JCO.2013.53.0105
20. J.D. Wolchok, B. Neyns, G. Linette, S. Negrier, J. Lutzky, L. Thomas, and et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol 11 2010 155 164 10.1016/S1470-2045(09)70334-1
21. A.V. Maker, J.C. Yang, R.M. Sherry, S.L. Topalian, U.S. Kammula, R.E. Royal, and et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma J Immunother Hagerstown Md 1997 29 2006 455 463 10.1097/01.cji.0000208259.73167.58
22. M. Nishino, L.M. Sholl, F.S. Hodi, H. Hatabu, and N.H. Ramaiya Anti-PD-1-related pneumonitis during cancer immunotherapy N Engl J Med 373 2015 288 290 10.1056/NEJMc1505197
23. M. Johncilla, J. Misdraji, D.S. Pratt, A.T. Agoston, G.Y. Lauwers, A. Srivastava, and et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a Series of 11 Cases Am J Surg Pathol 2015 10.1097/PAS.0000000000000453
24. S. Orlov, F. Salari, L. Kashat, and P.G. Walfish Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies J Clin Endocrinol Metab 100 2015 1738 1741 10.1210/jc.2014-4560
25. S. Iwama, A. De Remigis, M.K. Callahan, S.F. Slovin, J.D. Wolchok, and P. Caturegli Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody Sci Transl Med 6 2014 230ra45 10.1126/scitranslmed.3008002
26. Merck Highlights of prescribing information for Keytruda 2015
27. Bristol-Myers Squibb Yervoy (Ipilimumab), immune-mediated adverse reaction management guide 2011
28. K.E. Beck, J.A. Blansfield, K.Q. Tran, A.L. Feldman, M.S. Hughes, R.E. Royal, and et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 J Clin Oncol Off J Am Soc Clin Oncol 24 2006 2283 2289 10.1200/JCO.2005.04.5716
29. A. Kronbichler, D.R.W. Jayne, and G. Mayer Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis Eur J Clin Invest 45 2015 346 368 10.1111/eci.12410
30. M.E.B. Smith, E. Haney, M. McDonagh, M. Pappas, M. Daeges, N. Wasson, and et al. Treatment of myalgic encephalomyelitis/chronic fatigue syndrome: a systematic review for a National Institutes of Health Pathways to Prevention Workshop Ann Intern Med 162 2015 841 850 10.7326/M15-0114
31. T. Powles, J.P. Eder, G.D. Fine, F.S. Braiteh, Y. Loriot, C. Cruz, and et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 2014 558 562 10.1038/nature13904
32. R.L. Johnston, J. Lutzky, A. Chodhry, and J.S. Barkin Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab Dig Dis Sci 54 2009 2538 2540 10.1007/s10620-008-0641-z
33. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.-J. Hwu, R. Kefford, and et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 2013 134 144 10.1056/NEJMoa1305133
34. K.W. Kim, N.H. Ramaiya, K.M. Krajewski, J.P. Jagannathan, S.H. Tirumani, A. Srivastava, and et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings Invest New Drugs 31 2013 1071 1077 10.1007/s10637-013-9939-6
35. P.J. Johnson, I.G. McFarlane, and R. Williams Azathioprine for long-term maintenance of remission in autoimmune hepatitis N Engl J Med 333 1995 958 963 10.1056/NEJM199510123331502
36. G. Berthod, R. Lazor, I. Letovanec, E. Romano, L. Noirez, J. Mazza Stalder, and et al. Pulmonary sarcoid-like granulomatosis induced by ipilimumab J Clin Oncol Off J Am Soc Clin Oncol 30 2012 e156 e159 10.1200/JCO.2011.39.3298
37. A. Eckert, A. Schoeffler, S. Dalle, A. Phan, L. Kiakouama, and L. Thomas Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient Dermatol Basel Switz 218 2009 69 70 10.1159/000161122
38. I.Z. Barjaktarevic, N. Qadir, A. Suri, J.T. Santamauro, and D. Stover Organizing pneumonia as a side effect of ipilimumab treatment of melanoma Chest 143 2013 858 861 10.1378/chest.12-1467
39. J.S. Weber, K.C. Kähler, and A. Hauschild Management of immune-related adverse events and kinetics of response with ipilimumab J Clin Oncol Off J Am Soc Clin Oncol 30 2012 2691 2697 10.1200/JCO.2012.41.6750
40. M. Ryder, M. Callahan, M.A. Postow, J. Wolchok, and J.A. Fagin Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution Endocr Relat Cancer 21 2014 371 381 10.1530/ERC-13-0499
41. A. Faje Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights Pituitary 2015 10.1007/s11102-015-0671-4
42. A. Ribas, L.H. Camacho, G. Lopez-Berestein, D. Pavlov, C.A. Bulanhagui, R. Millham, and et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206 J Clin Oncol Off J Am Soc Clin Oncol 23 2005 8968 8977 10.1200/JCO.2005.01.109
43. M. Ramos-Casals, A.G. Tzioufas, J.H. Stone, A. Sisó, and X. Bosch Treatment of primary Sjögren syndrome: a systematic review JAMA 304 2010 452 460 10.1001/jama.2010.1014
44. E. Papavasileiou, S. Prasad, S.K. Freitag, L. Sobrin, and A.-M. Lobo Ipilimumab-induced ocular and orbital inflammation-a case series and review of the literature Ocul Immunol Inflamm 2015 1 7 10.3109/09273948.2014.1001858
45. M.R. Robinson, C.-C. Chan, J.C. Yang, B.I. Rubin, G.J. Gracia, H.N. Sen, and et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis J Immunother Hagerstown Md 1997 27 2004 478 479
46. S. Wilgenhof, and B. Neyns Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient Ann Oncol Off J Eur Soc Med Oncol ESMO 22 2011 991 993 10.1093/annonc/mdr028
47. I. Bot, C.U. Blank, W. Boogerd, and D. Brandsma Neurological immune-related adverse events of ipilimumab Pract Neurol 13 2013 278 280 10.1136/practneurol-2012-000447
48. M. Maur, C. Tomasello, A. Frassoldati, M.V. Dieci, E. Barbieri, and P. Conte Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma J Clin Oncol Off J Am Soc Clin Oncol 30 2012 e76 e78 10.1200/JCO.2011.38.7886
49. S. Bhatia, B.R. Huber, M.P. Upton, and J.A. Thompson Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report J Immunother Hagerstown Md 1997 32 2009 203 205 10.1097/CJI.0b013e318193a206
50. B. Liao, S. Shroff, C. Kamiya-Matsuoka, and S. Tummala Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma Neuro-Oncol 16 2014 589 593 10.1093/neuonc/nou001
51. M.A. Postow, J. Chesney, A.C. Pavlick, C. Robert, K. Grossmann, D. McDermott, and et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N Engl J Med 372 2015 2006 2017 10.1056/NEJMoa1414428
52. C.J. Voskens, S.M. Goldinger, C. Loquai, C. Robert, K.C. Kaehler, C. Berking, and et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network PloS One 8 2013 e53745 10.1371/journal.pone.0053745
53. S. Andrews, and R. Holden Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma Cancer Manag Res 4 2012 299 307 10.2147/CMAR.S31873
54. F. Fadel, K. El Karoui, and B. Knebelmann Anti-CTLA4 antibody-induced lupus nephritis N Engl J Med 361 2009 211 212 10.1056/NEJMc0904283
55. B.L. Goldstein, L. Gedmintas, and D.J. Todd Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4 Arthritis Rheumatol Hoboken NJ 66 2014 768 769 10.1002/art.38282
56. J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow, N.A. Rizvi, A.M. Lesokhin, and et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133 10.1056/NEJMoa1302369
57. P.M. Forde, K. Rock, G. Wilson, and K.J. O'Byrne Ipilimumab-induced immune-related renal failure-a case report Anticancer Res 32 2012 4607 4608
58. H. Izzedine, V. Gueutin, C. Gharbi, C. Mateus, C. Robert, E. Routier, and et al. Kidney injuries related to ipilimumab Invest New Drugs 32 2014 769 773 10.1007/s10637-014-0092-7
59. C. Robert, A. Ribas, J.D. Wolchok, F.S. Hodi, O. Hamid, R. Kefford, and et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Lancet 384 2014 1109 1117 10.1016/S0140-6736(14)60958-2
60. A.M. Di Giacomo, R. Danielli, M. Guidoboni, L. Calabrò, D. Carlucci, C. Miracco, and et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases Cancer Immunol Immunother CII 58 2009 1297 1306 10.1007/s00262-008-0642-y
61. P.A. Banks, T.L. Bollen, C. Dervenis, H.G. Gooszen, C.D. Johnson, M.G. Sarr, and et al. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus Gut 62 2013 102 111 10.1136/gutjnl-2012-302779
62. P. Armand, A. Nagler, E.A. Weller, S.M. Devine, D.E. Avigan, Y.-B. Chen, and et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial J Clin Oncol Off J Am Soc Clin Oncol 31 2013 4199 4206 10.1200/JCO.2012.48.3685
63. I.O. Gordon, T. Wade, K. Chin, J. Dickstein, and T.F. Gajewski Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma Cancer Immunol Immunother CII 58 2009 1351 1353 10.1007/s00262-008-0627-x
64. M. Akhtari, E.K. Waller, D.L. Jaye, D.H. Lawson, R. Ibrahim, N.E. Papadopoulos, and et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody) J Immunother Hagerstown Md 1997 32 2009 322 324 10.1097/CJI.0b013e31819aa40b
65. P. du Rusquec, M. Saint-Jean, A. Brocard, L. Peuvrel, A. Khammari, G. Quéreux, and et al. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma J Immunother Hagerstown Md 1997 37 2014 348 350 10.1097/CJI.0000000000000041
66. J. Delyon, C. Mateus, and T. Lambert Hemophilia A induced by ipilimumab N Engl J Med 365 2011 1747 1748 10.1056/NEJMc1110923
67. A. Ribas, R. Kefford, M.A. Marshall, C.J.A. Punt, J.B. Haanen, M. Marmol, and et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma J Clin Oncol Off J Am Soc Clin Oncol 31 2013 616 622 10.1200/JCO.2012.44.6112
68. E.D. Kwon, C.G. Drake, H.I. Scher, K. Fizazi, A. Bossi, A.J.M. van den Eertwegh, and et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial Lancet Oncol 15 2014 700 712 10.1016/S1470-2045(14)70189-5
69. E.B. Garon, N.A. Rizvi, R. Hui, N. Leighl, A.S. Balmanoukian, J.P. Eder, and et al. Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2015 2018 2028 10.1056/NEJMoa1501824
70. S.N. Gettinger, L. Horn, L. Gandhi, D.R. Spigel, S.J. Antonia, N.A. Rizvi, and et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol Off J Am Soc Clin Oncol 2015 10.1200/JCO.2014.58.3708
71. R.S. Herbst, J.-C. Soria, M. Kowanetz, G.D. Fine, O. Hamid, M.S. Gordon, and et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567 10.1038/nature14011
72. B. Vaidya, S.H.S. Pearce, S. Charlton, N. Marshall, A.D. Rowan, I.D. Griffiths, and et al. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies Rheumatol Oxf Engl 41 2002 180 183
73. A. Zhernakova, P. Eerligh, P. Barrera, J.Z. Wesoly, J.Z. Weseloy, T.W.J. Huizinga, and et al. CTLA4 is differentially associated with autoimmune diseases in the Dutch population Hum Genet 118 2005 58 66 10.1007/s00439-005-0006-z
74. P. Jin, B. Xiang, G. Huang, and Z. Zhou The association of cytotoxic T-lymphocyte antigen-4 + 49A/G and CT60 polymorphisms with type 1 diabetes and latent autoimmune diabetes in Chinese adults J Endocrinol Invest 2014 10.1007/s40618-014-0162-x
75. G.G. Song, J.-H. Kim, Y.H. Kim, and Y.H. Lee Association between CTLA-4 polymorphisms and susceptibility to Celiac disease: a meta-analysis Hum Immunol 74 2013 1214 1218 10.1016/j.humimm.2013.05.014
76. M. Fernández-Mestre, K. Sánchez, O. Balbás, K. Gendzekhzadze, V. Ogando, M. Cabrera, and et al. Influence of CTLA-4 gene polymorphism in autoimmune and infectious diseases Hum Immunol 70 2009 532 535 10.1016/j.humimm.2009.03.016
77. L.L. Hudson, K. Rocca, Y.W. Song, and J.P. Pandey CTLA-4 gene polymorphisms in systemic lupus erythematosus: a highly significant association with a determinant in the promoter region Hum Genet 111 2002 452 455 10.1007/s00439-002-0807-2
78. G.K. Bertsias, M. Nakou, C. Choulaki, A. Raptopoulou, E. Papadimitraki, G. Goulielmos, and et al. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus Arthritis Rheum 60 2009 207 218 10.1002/art.24227
79. Y.H. Lee, S.-C. Bae, J.-H. Kim, and G.G. Song Meta-analysis of genetic polymorphisms in programmed cell death 1: associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility Z Rheumatol 74 2015 230 239 10.1007/s00393-014-1415-y